Effectiveness of Oral Cephalexin-Clavulanic Acid, Cefuroxime, and Amoxicillin-Clavulanic Acid in the Management of Dental Infections: A Real-World, Retrospective, Electronic Medical Record-Based Study in India.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
accepted:
08
11
2023
medline:
18
12
2023
pubmed:
18
12
2023
entrez:
18
12
2023
Statut:
aheadofprint
Résumé
Despite multiple antibiotics being available to manage dental infections (DI), there is lack of data comparing commonly prescribed antibiotics in India. The aim of this study was to evaluate the real-world effectiveness and tolerability of cephalexin-clavulanic acid fixed-dose combination (cephalexin CV FDC) in contrast with amoxicillin-clavulanic acid (co-amoxiclav FDC) and cefuroxime among patients with dental infections (odontogenic) in India. This retrospective, multi-centric, observational, real-world electronic medical record (EMR)-based study was conducted between January 2022 and December 2022. The EMRs of 355 adults with DI receiving oral cephalexin CV, co-amoxiclav, or cefuroxime were categorized into two distinct groups: Group I (Test Group) with patients prescribed cephalexin extended release 375/750 mg along with clavulanic acid 125 mg; and Group II (Comparator Group) with patients prescribed co-amoxiclav 625 mg (500 mg amoxicillin + 125 mg clavulanic acid) or cefuroxime (250 mg/500 mg). Toothache was the most common complaint, reported by 95.5% of patients, followed by swelling (46.8%), tooth sensitivity (35.5%), pus discharge (33.0%), redness and halitosis (30.4% each). Dental caries was observed in 81.1% of patients. Clinical improvement, defined as improvement/partial resolution of infection-related clinical signs and symptoms (composite measure of pain, swelling, fever, requirement of additional antimicrobial therapy) as per dentists' judgment, was recorded in 98.3% of patients with cephalexin CV, 96.8% of patients with co-amoxiclav, and 98.9% of patients treated with cefuroxime within 10 days. Time (days) to clinical improvement was numerically lesser among patients receiving cephalexin CV (4.6 ± 2.0) compared with cefuroxime (4.9 ± 2.1) and co-amoxiclav (5.0 ± 2.6). All treatments were well tolerated. Cephalexin CV was as effective as co-amoxiclav and cefuroxime, with faster clinical improvement and better resolution of certain symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Despite multiple antibiotics being available to manage dental infections (DI), there is lack of data comparing commonly prescribed antibiotics in India.
OBJECTIVES
OBJECTIVE
The aim of this study was to evaluate the real-world effectiveness and tolerability of cephalexin-clavulanic acid fixed-dose combination (cephalexin CV FDC) in contrast with amoxicillin-clavulanic acid (co-amoxiclav FDC) and cefuroxime among patients with dental infections (odontogenic) in India.
METHODS
METHODS
This retrospective, multi-centric, observational, real-world electronic medical record (EMR)-based study was conducted between January 2022 and December 2022. The EMRs of 355 adults with DI receiving oral cephalexin CV, co-amoxiclav, or cefuroxime were categorized into two distinct groups: Group I (Test Group) with patients prescribed cephalexin extended release 375/750 mg along with clavulanic acid 125 mg; and Group II (Comparator Group) with patients prescribed co-amoxiclav 625 mg (500 mg amoxicillin + 125 mg clavulanic acid) or cefuroxime (250 mg/500 mg).
RESULTS
RESULTS
Toothache was the most common complaint, reported by 95.5% of patients, followed by swelling (46.8%), tooth sensitivity (35.5%), pus discharge (33.0%), redness and halitosis (30.4% each). Dental caries was observed in 81.1% of patients. Clinical improvement, defined as improvement/partial resolution of infection-related clinical signs and symptoms (composite measure of pain, swelling, fever, requirement of additional antimicrobial therapy) as per dentists' judgment, was recorded in 98.3% of patients with cephalexin CV, 96.8% of patients with co-amoxiclav, and 98.9% of patients treated with cefuroxime within 10 days. Time (days) to clinical improvement was numerically lesser among patients receiving cephalexin CV (4.6 ± 2.0) compared with cefuroxime (4.9 ± 2.1) and co-amoxiclav (5.0 ± 2.6). All treatments were well tolerated.
CONCLUSION
CONCLUSIONS
Cephalexin CV was as effective as co-amoxiclav and cefuroxime, with faster clinical improvement and better resolution of certain symptoms.
Identifiants
pubmed: 38109028
doi: 10.1007/s40801-023-00406-x
pii: 10.1007/s40801-023-00406-x
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Ortiz R, Espinoza V. Odontogenic infection. Review of the pathogenesis, diagnosis, complications and treatment. Res Rep Oral Maxillofac Surg. 2021;5:055.
Neal TW, Schlieve T. Complications of severe odontogenic infections: a review. Biology (Basel). 2022. https://doi.org/10.3390/biology11121784 .
doi: 10.3390/biology11121784
pubmed: 36552293
Ogle OE. Odontogenic infections. Dent Clin North Am. 2017;61:235–52. https://doi.org/10.1016/j.cden.2016.11.004 .
doi: 10.1016/j.cden.2016.11.004
pubmed: 28317564
Bernabe E, Marcenes W, Hernandez CR, Bailey J, Abreu LG, Alipour V, Amini S, Arabloo J, Arefi Z, Arora A, et al. Global, regional, and national levels and trends in burden of oral conditions from 1990 to 2017: a systematic analysis for the global burden of disease 2017 study. J Dent Res. 2020;99:362–73. https://doi.org/10.1177/0022034520908533 .
doi: 10.1177/0022034520908533
pubmed: 32122215
Erazo D, Whetstone DR. Dental infections. StatPearls Publishing; 2023.
Gonçalves L, Lauriti L, Yamamoto MK, Luz JG. Characteristics and management of patients requiring hospitalization for treatment of odontogenic infections. J Craniofac Surg. 2013;24:e458-462. https://doi.org/10.1097/SCS.0b013e3182902e95 .
doi: 10.1097/SCS.0b013e3182902e95
pubmed: 24036813
Patil R, Gondivkar SM, Gadbail AR, Yuwanati M, Mankar M, Likhitkar M, Sarode S, Sarode G, Patil S. Role of oral foci in systemic diseases: an update. Int J Contemp Dent Med Rev. 2017. https://doi.org/10.15713/ins.ijcdmr.115 .
doi: 10.15713/ins.ijcdmr.115
Seymour RA. Is gum disease killing your patient? Br Dent J. 2009;206:551–2. https://doi.org/10.1038/sj.bdj.2009.472 .
doi: 10.1038/sj.bdj.2009.472
pubmed: 19461642
Donkor ES, Kotey FC. Methicillin-resistant Staphylococcus aureus in the oral cavity: implications for antibiotic prophylaxis and surveillance. Infect Dis. 2020;13:1178633720976581. https://doi.org/10.1177/1178633720976581 .
doi: 10.1177/1178633720976581
Meinen A, Reuss A, Willrich N, Feig M, Noll I, Eckmanns T, Al-Nawas B, Markwart R. Antimicrobial resistance and the spectrum of pathogens in dental and oral-maxillofacial infections in hospitals and dental practices in Germany. Front Microbiol. 2021;12: 676108. https://doi.org/10.3389/fmicb.2021.676108 .
doi: 10.3389/fmicb.2021.676108
pubmed: 34149666
pmcid: 8206268
Garbacz K, Jarzembowski T, Kwapisz E, Daca A, Witkowski J. Do the oral Staphylococcus aureus strains from denture wearers have a greater pathogenicity potential? J Oral Microbiol. 2018;11:1536193. https://doi.org/10.1080/20002297.2018.1536193 .
doi: 10.1080/20002297.2018.1536193
pubmed: 30598731
pmcid: 6225501
Kumar N, Khare VV, Jamdade A, Aggarwal A, Rathore NS, Yadav S. Antibiotic susceptibility of the bacteria causing odontogenic infections: an observational study. J Indian Acad Oral Med Radiol. 2022;34:442–6. https://doi.org/10.4103/jiaomr.jiaomr_194_22 .
doi: 10.4103/jiaomr.jiaomr_194_22
Ahmadi H, Ebrahimi A, Ahmadi F. Antibiotic therapy in dentistry. Int J Dent. 2021;2021:6667624. https://doi.org/10.1155/2021/6667624 .
doi: 10.1155/2021/6667624
pubmed: 33574843
pmcid: 7861949
MoHFW. Standard Treatment guidelines for Oral Health. 2010. Available from: https://main.mohfw.gov.in/sites/default/files/N_56820_1613385504626.pdf . Accessed 12 June 2023.
Ramu C, Padmanabhan TV. Indications of antibiotic prophylaxis in dental practice—review. Asian Pac J Trop Biomed. 2012;2:749–54. https://doi.org/10.1016/s2221-1691(12)60222-6 .
doi: 10.1016/s2221-1691(12)60222-6
pubmed: 23570007
pmcid: 3609373
Bui T, Preuss CV. Cephalosporins. StatPearls Publishing; 2022.
Tartaglione TA, Polk RE. Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime. Drug Intell Clin Pharm. 1985;19:188–98. https://doi.org/10.1177/106002808501900304 .
doi: 10.1177/106002808501900304
pubmed: 3884304
Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23:160–201. https://doi.org/10.1128/cmr.00037-09 .
doi: 10.1128/cmr.00037-09
pubmed: 20065329
pmcid: 2806661
Sobottka I, Cachovan G, Stürenburg E, Ahlers MO, Laufs R, Platzer U, Mack D. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother. 2002;46:4019–21. https://doi.org/10.1128/aac.46.12.4019-4021.2002 .
doi: 10.1128/aac.46.12.4019-4021.2002
pubmed: 12435716
pmcid: 132736
Kumar KP, Kaushik M, Kumar PU, Reddy MS, Prashar N. Antibiotic prescribing habits of dental surgeons in hyderabad city, India, for pulpal and periapical pathologies: a survey. Adv Pharmacol Sci. 2013;2013: 537385. https://doi.org/10.1155/2013/537385 .
doi: 10.1155/2013/537385
pubmed: 24187549
pmcid: 3804281
WHO global oral health report. 2022. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/odi.14516 . Accessed 22 June 2023.
Haque M, Sartelli M, Haque SZ. Dental infection and resistance-global health consequences. Dent J (Basel). 2019. https://doi.org/10.3390/dj7010022 .
doi: 10.3390/dj7010022
pubmed: 30823670
Monasteri R, Henriquez SG. Prevalence and characterization of Odontogenic Infections in the Public Assistance Emergency Hospital between the Months of July to September of the Year 2015: Prospective Study. EC Dental Science. 2018;17:880–91.
Topazian RG, Goldberg MH, Hupp JR. Oral and maxillofacial infections. Saunders; 2002.
Seppänen L, Rautemaa R, Lindqvist C, Lauhio A. Changing clinical features of odontogenic maxillofacial infections. Clin Oral Investig. 2010;14:459–65. https://doi.org/10.1007/s00784-009-0281-5 .
doi: 10.1007/s00784-009-0281-5
pubmed: 19449042
Mahmoodi B, Weusmann J, Azaripour A, Braun B, Walter C, Willershausen B. Odontogenic infections: a 1-year retrospective study. J Contemp Dent Pract. 2015;16:253–8. https://doi.org/10.5005/jp-journals-10024-1671 .
doi: 10.5005/jp-journals-10024-1671
pubmed: 26067725
Tadjoedin FM, Fitri AH, Kuswandani SO, Sulijaya B, Soeroso Y. The correlation between age and periodontal diseases. J Int Dental Med Res. 2017;10:327.
Hunt DE, King TJ, Fuller GE. Antibiotic suseptibility of bacteria isolated from oral infections. J Oral Surg. 1978;36:527–9.
pubmed: 277637
Pandey P, Nandkeoliar T, Tikku AP, Singh D, Singh MK. Prevalence of dental caries in the Indian population: a systematic review and meta-analysis. J Int Soc Prev Community Dent. 2021;11:256–65. https://doi.org/10.4103/jispcd.JISPCD_42_21 .
doi: 10.4103/jispcd.JISPCD_42_21
pubmed: 34268187
pmcid: 8257015
Shakya N, Sharma D, Newaskar V, Agrawal D, Shrivastava S, Yadav R. Epidemiology, microbiology and antibiotic sensitivity of odontogenic space infections in Central India. J Maxillofac Oral Surg. 2018;17:324–31. https://doi.org/10.1007/s12663-017-1014-y .
doi: 10.1007/s12663-017-1014-y
pubmed: 30034150
WHO. Oral health. 2023. Available from: https://cdn.who.int/media/docs/default-source/ncds/mnd/oral-health/eb152-draft-global-oral-health-action-plan-2023-2030-en.pdf . Accessed 22 June 2023.
Maheswaran T, Ramesh V, Krishnan A, Joseph J. Common chief complaints of patients seeking treatment in the government dental institution of Puducherry, India. J Indian Acad Dent Spec Res. 2015;2:55–8.
doi: 10.4103/2229-3019.177921
Abdullah BA, Al-Tuhafi AA. Chief complaints of patients attending college of Dentistry at Mosul University. Al-Rafidain Dental J. 2007;7:201–5.
doi: 10.33899/rden.2007.39756
Masiga M. Presenting chief complaints and clinical characteristics among patients attending the Department of Paediatric Dentistry Clinic at the University of Nairobi Dental Hospital. East Afr Med J. 2005;82:652–5.
pubmed: 16619711
Labh AK, Ramani P. Prevalence of periodontal abscess among patients visiting a private dental college and hospital in Chennai, India. Indian J Forensic Med Toxicol. 2020;14:5081–92.
Sanders JL, Houck RC. Dental abscess. Treasure Island: StatPearls Publishing LLC; 2023.
Henry M, Reader A, Beck M. Effect of penicillin on postoperative endodontic pain and swelling in symptomatic necrotic teeth. Journal of endodontics. 2001;27:117–23.
doi: 10.1097/00004770-200102000-00016
pubmed: 11491635
Tancawan AL, Pato MN, Abidin KZ, Asari AS, Thong TX, Kochhar P, Muganurmath C, Twynholm M, Barker K. Amoxicillin/clavulanic acid for the treatment of odontogenic infections: a randomised study comparing efficacy and tolerability versus clindamycin. Int J Dent. 2015;2015: 472470. https://doi.org/10.1155/2015/472470 .
doi: 10.1155/2015/472470
pubmed: 26300919
pmcid: 4537712
Kumari S, Mohanty S, Sharma P, Dabas J, Kohli S, Diana C. Is the routine practice of antibiotic prescription and microbial culture and antibiotic sensitivity testing justified in primary maxillofacial space infection patients? A prospective, randomized clinical study. J Craniomaxillofac Surg. 2018;46:446–52. https://doi.org/10.1016/j.jcms.2017.11.026 .
doi: 10.1016/j.jcms.2017.11.026
pubmed: 29311020
Lockhart PB, Tampi MP, Abt E, Aminoshariae A, Durkin MJ, Fouad AF, Gopal P, Hatten BW, Kennedy E, Lang MS, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: a report from the American Dental Association. J Am Dent Assoc. 2019;150:906-921.e912. https://doi.org/10.1016/j.adaj.2019.08.020 .
doi: 10.1016/j.adaj.2019.08.020
pubmed: 31668170
pmcid: 8270006
Horii M, Morinaga T, Shimada S, Takeuchi T, Yamanaka H, Nishimura T, Noshi Y, Okada T, Sasaki T, Ikeda S, et al. Double-blind comparison of L-keflex and cephalexin (Keflex) in dental infections (author’s transl). Jpn J Antibiot. 1980;33:1194–214.
pubmed: 7017189
Matijević S, Lazić Z, Kuljić-Kapulica N, Nonković Z. Empirical antimicrobial therapy of acute dentoalveolar abscess. Vojnosanit Pregl. 2009;66:544–50. https://doi.org/10.2298/vsp0907544m .
doi: 10.2298/vsp0907544m
pubmed: 19678579
Buttar R, Aleksejūnienė J, Coil J. Antibiotic and opioid analgesic prescribing patterns of dentists in Vancouver and endodontic specialists in British Columbia. J Can Dent Assoc. 2017;83: h8.
pubmed: 29513210
Maslamani M, Sedeqi F. Antibiotic and analgesic prescription patterns among dentists or management of dental pain and infection during endodontic treatment. Med Princ Pract. 2018;27:66–72. https://doi.org/10.1159/000486416 .
doi: 10.1159/000486416
pubmed: 29262417
Dana R, Azarpazhooh A, Laghapour N, Suda KJ, Okunseri C. Role of dentists in prescribing opioid analgesics and antibiotics: an overview. Dent Clin North Am. 2018;62:279–94. https://doi.org/10.1016/j.cden.2017.11.007 .
doi: 10.1016/j.cden.2017.11.007
pubmed: 29478458
Sasaki I, Morihana T, Kaneko A, Michi K, Takahashi K, Fukuoka F, Satoh T, Yoshinari N, Ohne M, Hara H, et al. Clinical evaluation of cefuroxime axetil in acute dental infections. Double blind comparative study vs. cefaclor. Jpn J Antibiot. 1990;43:2035–68.
pubmed: 2086820
Kuriyama T, Karasawa T, Nakagawa K, Nakamura S, Yamamoto E. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics. Oral Microbiol Immunol. 2002;17:285–9. https://doi.org/10.1034/j.1399-302x.2002.170504.x .
doi: 10.1034/j.1399-302x.2002.170504.x
pubmed: 12354209
Al-Qamachi LH, Aga H, McMahon J, Leanord A, Hammersley N. Microbiology of odontogenic infections in deep neck spaces: a retrospective study. Br J Oral Maxillofac Surg. 2010;48:37–9. https://doi.org/10.1016/j.bjoms.2008.12.007 .
doi: 10.1016/j.bjoms.2008.12.007
pubmed: 19178989